Yuksel 2010.

Methods	Design: RT Groups: intervention group (osteoporosis risk management); control group (usual care)
Participants	Pharmacy worker: not targeted ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ Pharmacy user: 262 patients with osteoporosis (129 intervention; 133 control) mean age: intervention 61 years; control 63 years % female: intervention 62%; control 67% Setting: unclear Country: Canada
Interventions	Pharmacy worker‐directed intervention: not reported ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ Pharmacy user‐directed intervention: patients received tailored education program on aspects of osteoporosis; including risk factors, bone mineral density testing, lifestyle measures, calcium and vitamin D intake, and medications and written information, and discussion of heel ultrasound Delivered by: pharmacists Type: behaviour change Mode of delivery: individual face‐to‐face; written materials TDF: knowledge, environment, context, resources Duration: 30‐minute consultation Pharmacy user control: usual treatment and information provided by pharmacy
Outcomes	Pharmacy worker: not assessed ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ Pharmacy user: Clinical: bone mineral density Psychological health: not assessed Behavioural: calcium and Vitamin D intake Quality of life: SF‐12 and Osteoporosis Targeted Quality of Life questionnaire (OPTQoL) Process: not assessed Costs: not assessed
Notes	Study/intervention name: OSTEOPHARM (no expansion of acronym provided). By a grant from the Institute of Health Economics (Edmonton) and Faculty Start Up Grant to Nesé Yuksel from the Faculty of Pharmacy and Pharmaceutical Sciences (University of Alberta) Yuksel 2006 (cited under Yuksel 2010) also refers to this study.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Internet randomisation
Allocation concealment (selection bias)	Low risk	Internet randomisation
Baseline outcome measures similar	Low risk	Similar
Baseline characteristics similar	Low risk	Similar ‐ control group had higher family history of osteoporosis but unlikely to change result
Incomplete outcome data (attrition bias) All outcomes	Low risk	Used intention‐to‐treat analysis; similar dropout in both groups
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinded
Protection against contamination	High risk	Both groups were based in the same pharmacies
Selective reporting (reporting bias)	Low risk	Not noted
Other bias	Low risk	Not noted
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not blinded

BMI: body‐mass index; BP: blood pressure; cluster‐RT: cluster randomised trial; COPD: chronic obstructive pulmonary disease; CV: cardiovascular; CVD: cardiovascular disease; DBP: diastolic blood pressure; EQ‐5D: Euroqol Measure of quality of life; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; GP: general practitioner (family doctor); HbA1c: glycosylated haemoglobin; HCU: health care utilisation; HDL: high‐density lipoprotein; HDL‐C: high‐density lipoprotein cholesterol; LDL: low‐density lipoprotein; LDL‐C: low‐density lipoprotein cholesterol; NHS: National Health Service; PEF: peak expiratory flow; PEFR: peak expiratory flow rate; RT: randomised trial; SBP: systolic blood pressure; SD: standard deviation; SF‐12: short form‐12; STD: sexually transmitted disease; TC: total cholesterol; TDF: theoretical domains framework; WHO: World Health Organization